Skip to main
AQST
AQST logo

AQST Stock Forecast & Price Target

AQST Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aquestive Therapeutics Inc. is well-positioned for growth due to its promising product pipeline, particularly in the no-needle epinephrine market, which is expected to drive significant revenue opportunities. The recent announcement that the FDA does not require an AdCom for its NDA of Anaphylm has positively influenced the company’s stock price, showcasing investor confidence in the potential approval of this innovative product. The combination of a strong portfolio, including established drugs like Suboxone and the anticipated approval of new therapies, supports a positive financial outlook for the company.

Bears say

Aquestive Therapeutics faces significant downside risks that contribute to a negative outlook on its stock, primarily stemming from the potential unsuccessful development of its product AQST-109. Additionally, there is an expectation of greater than anticipated revenue erosion from its licensed commercial products, which could severely impact overall financial performance. The company may also face the necessity of raising capital to strengthen its balance sheet, further complicating its financial stability amid these existing challenges.

AQST has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aquestive Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aquestive Therapeutics Inc (AQST) Forecast

Analysts have given AQST a Buy based on their latest research and market trends.

According to 5 analysts, AQST has a Buy consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aquestive Therapeutics Inc (AQST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.